The Occurrence, Evolution and Treatment of Glioblastoma 2.0

Dear Colleagues,

Of the 100,000 new cases of diffuse gliomas diagnosed every year worldwide, approximately 75% are glioblastoma(GBM). Novel therapeutics over the past couple of decades have only met with limited success, and median survival remains at 14 to 17 months. However, recent advances in gene profiling and proteomics have led to significant breakthroughs in the taxonomy, classification, and grading of both adults and pediatric brain gliomas. The aim of this Special Issue is to shed light on the molecular heterogeneity of this tumor in both adults and children, as well as to evaluate the benefits of multimodal treatment strategies involving surgery, radiotherapy, and chemotherapy. With new drug candidates now at different stages of clinical development, this approach takes full advantage of research on molecular and gene profiling to ensure ever more precise diagnoses as well as new promising treatments.

We welcome submissions, including original papers and reviews. Our Special Issue will focus on, but is not restricted to, the following:

• Tumor signatures in primary vs. secondary gliomas;
• The role of recently identified biomarkers in both the prognosis and treatment of pediatric gliomas;
• Role of checkpoints inhibitors in low- and high-grade gliomas;
• Mechanisms of recurrence of high-grade gliomas;
• Molecular and radiological features in low-grade gliomas shifting into high-grade gliomas;
• Role of re-surgery and re-radiation in recurrent GBMs;
• New developments in the armamentarium of pre-, intra-, and post-operative tools for the treatment of newly diagnosed/recurrent GBMs;
• Role of radiomics and neuroimaging in deep-seeded and multifocal gliomas for improved patient treatment and information;
• Midbrain gliomas: management and prognosis.

Dr. Antonella Mangraviti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• GBM
• low-grade and high-grade
• pediatric diffuse gliomas
• signaling pathways in GBMs
• recurrent gliomas
• midbrain gliomas
• radiomics in brain tumors
• re-surgery and re-radiation in GBMs
• immunotherapy
• targeted therapies for GBMs